

Supporting Information (S1 File)

INCB054828 (pemigatinib), a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3, displays activity against genetically defined tumor models

Phillip C.C. Liu¹, Holly Koblish^{1*}, Liangxing Wu², Kevin Bowman¹, Sharon Diamond¹, Darlise DiMatteo¹, Yue Zhang¹, Michael Hansbury¹, Mark Rupar¹, Xiaoming Wen¹, Paul Collier¹, Patricia Feldman¹, Ronald Klabe¹, Krista A. Burke¹, Maxim Soloviev¹, Christine Gardiner¹, Xin He¹, Alla Volgina¹, Maryanne Covington¹, Bruce Ruggeri¹, Richard Wynn¹, Timothy C. Burn¹, Peggy Scherle¹, Swamy Yeleswaram¹, Wenqing Yao², Reid Huber¹, Gregory Hollis¹

¹Discovery Biology, Incyte Research Institute, Wilmington, Delaware, United States of America

²Discovery Chemistry, Incyte Research Institute, Wilmington, Delaware, United States of America

*Corresponding author


Email: hkoblish@incyte.com (HK); <https://orcid.org/0000-0002-9745-3561>

Original Western Blot Images


Blots were developed using enhanced chemiluminescence substrate Femto (Thermo Fisher, Waltham, MA; #34094) and imaged with the Azure Biosystems c300 (Dublin, CA).

Figure 2 Panel A: KG1a (FGFR1OP2-FGFR1)

p-FGFR (Y653/Y654)




FGFR1




p-ERK1/2 (T202/Y204)

INCB054828 (nM) 54 18 6 2 0.7 0.2 0.06 0



ERK1/2

INCB054828 (nM) 54 18 6 2 0.7 0.2 0.06 0



p-STAT5 (Y694)

INCB054828 (nM) 54 18 6 2 0.7 0.2 0.06 0





Figure 2 Panel B: RT-4 (*FGFR3-TACC3*)


p-FRS2 (Y436)

INCB054828 (nM) 500 100 25 5 1.25 0.25 0 X




FRS2

INCB054828 (nM) 500 100 25 5 1.25 0.25 0 X



p-ERK1/2 (T202/Y204)

INCB054828 (nM) 500 100 25 5 1.25 0.25 0 X



ERK1/2

INCB054828 (nM) 500 100 25 5 1.25 0.25 0 X

